New guidelines released by the National Kidney Foundation state that 20 million American adults with chronic kidney disease (CKD) should be considered in the highest risk group for developing cardiovascular disease. The guidelines, "Hypertension and Antihypertensive Agents in Chronic Kidney Disease," reported in the American Journal of Kidney Disease (May 2004), suggested that physicians can stabilize their kidney patients by reducing blood pressure levels to a maximum of 130/80 mm Hg.
The guidelines provide an integrated clinical action plan; key suggestions include:
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs